Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics

Amicus Therapeutics (FOLD) reported $169.06 million in revenue for the quarter ended September 2025, representing a year-over-year increase of 19.5%. EPS of $0.17 for the same period compares to $0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $164.76 million, representing a surprise of +2.61%. The company delivered an EPS surprise of +41.67%, with the consensus EPS estimate being $0.12.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Amicus Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:Geographic net product sales- Ex-U.S.: $98.79 million versus $100.21 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +15.8% change.Geographic net product sales- U.S.: $70.27 million compared to the $64.47 million average estimate based on two analysts. The reported number represents a change of +25.1% year over year.Net product sales- Pombiliti + Opfolda: $30.71 million versus $29.77 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +45.3% change.Net product sales- Galafold: $138.35 million versus the four-analyst average estimate of $150.1 million. The reported number represents a year-over-year change of +14.9%.View all Key Company Metrics for Amicus Therapeutics here>>>Shares of Amicus Therapeutics have returned +10.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.Zacks Names #1 Semiconductor StockThis under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be.With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028.See This Stock Now for Free >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amicus Therapeutics, Inc. (FOLD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks